MELBOURNE, Australia and INDIANAPOLIS, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the half-year ended 30 June 2025. All figures are in USD unless stated otherwise.
Related Questions
How does the reported revenue and earnings growth compare to Telix's guidance and analyst expectations for H1 2025?
What are the details of the announced investments for long‑term growth—capital allocation, R&D pipeline milestones, and potential dilution or financing needs?
How will the half‑year results impact Telix's valuation multiples relative to peers in the pharma sector and affect short‑term trading activity?